
|Videos|August 19, 2011
ASCO: Impact of 2 New Drugs for the Treatment of Metastatic Melanoma
Author(s)Antoni Ribas, MD, PhD
Dr. Antoni Ribas, UCLA’s Jonsson Comprehensive Cancer Center and a presenter at this year’s annual meeting of the American Society of Clinical Oncology, discusses the impact of 2 new drugs- ipilimumab (Yervoy) and vemurafenib (Zelboraf)-for the treatment of metastatic melanoma.
Advertisement
Dr. Antoni Ribas, UCLA's Jonsson Comprehensive Cancer Center and a presenter at this year's annual meeting of the American Society of Clinical Oncology, discusses the impact of 2 new drugs- ipilimumab (Yervoy) and vemurafenib (Zelboraf)-for the treatment of metastatic melanoma.
Newsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves Relacorilant Combo in Platinum-Resistant Ovarian Cancers
2
Navigating New Horizons in Neuroendocrine Prostate Cancer
3
Bevacizumab Biosimilar Shows Clinical Equivalence in Advanced NSCLC
4
The Intersection of Technology and Psycho-Oncology Care
5























































